284 related articles for article (PubMed ID: 12684396)
1. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.
Bergman PJ; McKnight J; Novosad A; Charney S; Farrelly J; Craft D; Wulderk M; Jeffers Y; Sadelain M; Hohenhaus AE; Segal N; Gregor P; Engelhorn M; Riviere I; Houghton AN; Wolchok JD
Clin Cancer Res; 2003 Apr; 9(4):1284-90. PubMed ID: 12684396
[TBL] [Abstract][Full Text] [Related]
2. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.
Bergman PJ; Camps-Palau MA; McKnight JA; Leibman NF; Craft DM; Leung C; Liao J; Riviere I; Sadelain M; Hohenhaus AE; Gregor P; Houghton AN; Perales MA; Wolchok JD
Vaccine; 2006 May; 24(21):4582-5. PubMed ID: 16188351
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
4. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles.
Goldberg SM; Bartido SM; Gardner JP; Guevara-Patiño JA; Montgomery SC; Perales MA; Maughan MF; Dempsey J; Donovan GP; Olson WC; Houghton AN; Wolchok JD
Clin Cancer Res; 2005 Nov; 11(22):8114-21. PubMed ID: 16299244
[TBL] [Abstract][Full Text] [Related]
6. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs.
Manley CA; Leibman NF; Wolchok JD; Rivière IC; Bartido S; Craft DM; Bergman PJ
J Vet Intern Med; 2011; 25(1):94-9. PubMed ID: 21143299
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor.
Grosenbaugh DA; Leard AT; Bergman PJ; Klein MK; Meleo K; Susaneck S; Hess PR; Jankowski MK; Jones PD; Leibman NF; Johnson MH; Kurzman ID; Wolchok JD
Am J Vet Res; 2011 Dec; 72(12):1631-8. PubMed ID: 22126691
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma.
Tagawa ST; Lee P; Snively J; Boswell W; Ounpraseuth S; Lee S; Hickingbottom B; Smith J; Johnson D; Weber JS
Cancer; 2003 Jul; 98(1):144-54. PubMed ID: 12833467
[TBL] [Abstract][Full Text] [Related]
9. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).
Meyer RG; Britten CM; Siepmann U; Petzold B; Sagban TA; Lehr HA; Weigle B; Schmitz M; Mateo L; Schmidt B; Bernhard H; Jakob T; Hein R; Schuler G; Schuler-Thurner B; Wagner SN; Drexler I; Sutter G; Arndtz N; Chaplin P; Metz J; Enk A; Huber C; Wölfel T
Cancer Immunol Immunother; 2005 May; 54(5):453-67. PubMed ID: 15627214
[TBL] [Abstract][Full Text] [Related]
10. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma.
Alexander AN; Huelsmeyer MK; Mitzey A; Dubielzig RR; Kurzman ID; Macewen EG; Vail DM
Cancer Immunol Immunother; 2006 Apr; 55(4):433-42. PubMed ID: 15965647
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients.
Quaglino P; Osella-Abate S; Cappello N; Ortoncelli M; Nardò T; Fierro MT; Cavallo F; Savoia P; Bernengo MG
Melanoma Res; 2007 Apr; 17(2):75-82. PubMed ID: 17496782
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
Ribas A; Camacho LH; Lopez-Berestein G; Pavlov D; Bulanhagui CA; Millham R; Comin-Anduix B; Reuben JM; Seja E; Parker CA; Sharma A; Glaspy JA; Gomez-Navarro J
J Clin Oncol; 2005 Dec; 23(35):8968-77. PubMed ID: 16204013
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
Stopeck AT; Jones A; Hersh EM; Thompson JA; Finucane DM; Gutheil JC; Gonzalez R
Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G
Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
19. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma.
Wolchok JD; Yuan J; Houghton AN; Gallardo HF; Rasalan TS; Wang J; Zhang Y; Ranganathan R; Chapman PB; Krown SE; Livingston PO; Heywood M; Riviere I; Panageas KS; Terzulli SL; Perales MA
Mol Ther; 2007 Nov; 15(11):2044-50. PubMed ID: 17726460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
